Health
Alzheimer’s blood test achieves faster diagnoses, high accuracy at Mayo Clinic
With nearly seven million Americans currently living with Alzheimer’s disease — and 13 million projected to have the illness by 2050 — early diagnosis and treatment are more urgent than ever.
To help address this, Mayo Clinic has announced a new, non-invasive blood test that detects a protein in the brain that signals Alzheimer’s.
The goal, doctors say, is for this test to offer a convenient, less invasive alternative to traditional diagnostic methods.
‘REVERSING’ ALZHEIMER’S: HERE ARE EXERCISES TO MAKE THE BRAIN MORE RESILIENT
Fox News Digital spoke to Dr. Alicia Algeciras-Schimnich, professor of laboratory medicine and pathology at Mayo Clinic Rochester in Minnesota, about the new test and what it means for Alzheimer’s patients and their families.
“This is the first Alzheimer’s disease blood test offered at Mayo Clinic Laboratories,” said Algeciras-Schimnich, who led the clinical validation study to gauge how well the test performed.
A new, non-invasive blood test detects a protein in the brain that signals Alzheimer’s, Mayo Clinic (not pictured) announced. (iStock)
“While there are other commercial blood tests for Alzheimer’s disease, the uniqueness of our test is its high accuracy rate.”
How does it work?
One of the hallmark features in the brains of patients with Alzheimer’s disease is the formation of plaque containing a protein known as beta amyloid.
“The pTau217 assay assesses the accumulation of beta amyloid in the brain by measuring the amount of phosphorylated Tau 217 (p-Tau217) in the test sample,” said Algeciras-Schimnich.
EXPERIMENTAL ALZHEIMER’S DRUG GETS FDA ADVISORY PANEL’S THUMBS-UP: ‘PROGRESS IS HAPPENING’
Accumulation of beta amyloid in the brain can also be evaluated by imaging techniques, such as PET scans or cerebrospinal fluid (CSF) biomarkers, the doctor noted — but those methods have some limitations.
“The PET scan to evaluate beta amyloid is expensive and not a widely available technology,” said Algeciras-Schimnich.
The Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota. Mayo Clinic has announced a new, non-invasive blood test to help determine if patients have Alzheimer’s. (iStock)
“And the CSF collection requires an invasive technique to remove spinal fluid, so it is also not widely used.”
The Alzheimer’s disease blood biomarkers serve as a non-invasive tool that can improve access for patients who need answers, she said.
How accurate is it?
In patients with symptoms of cognitive decline, the blood test has a sensitivity of 92% and a specificity of 96%.
“Sensitivity measures the ability of the test to correctly identify patients with the disease, while specificity measures the ability of the test to correctly identify those without the disease,” Algeciras-Schimnich explained.
“A blood-based test not only offers convenience, but could help transform Alzheimer’s disease research.”
Patients who take the test are classified as positive or negative for the presence of the accumulation of beta amyloid.
“In a small number of patients, the test will not be able to differentiate between the presence or absence of beta amyloid,” said Algeciras-Schimnich.
Patients who take the test are classified as positive or negative for the presence of the accumulation of beta amyloid. (iStock)
“These patients will need additional tests to determine if they are positive or negative for the accumulation of beta amyloid.”
The test is purposely designed to minimize the number of false positive results as compared to other tests, the doctor said.
“The test has been validated at Mayo Clinic through a rigorous quality process backed by scientific experts and clinicians,” Algeciras-Schimnich said.
The test is currently available for clinicians to order through Mayo Clinic Laboratories.
Evidence of Alzheimer’s disease is seen on PET scans at the Center for Alzheimer Research and Treatment (CART) at Brigham and Women’s Hospital in Boston, Massachusetts, March 2023. (REUTERS/Brian Snyder/File Photo)
“Since it is a blood test, it requires a blood draw by a phlebotomist, so anyone who is averse to blood should be aware,” said Algeciras-Schimnich.
At this point, the test is only recommended for individuals 50 years of age and older who have symptoms of mild cognitive impairment or mild dementia.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“We don’t yet have enough data to support how the test performs in younger individuals,” Algeciras-Schimnich said.
Michelle Rankine, PhD, a certified dementia practitioner in Texas, is not associated with Mayo Clinic but shared her comments on the test’s potential.
Accumulation of beta amyloid in the brain can also be evaluated by imaging techniques, such as PET scans or cerebrospinal fluid (CSF) biomarkers, the doctor noted — but those methods have some limitations. (Michael Robinson Chávez/The Washington Post)
“As the global burden of Alzheimer’s continues to rise, a blood-based test not only offers convenience, but could help transform Alzheimer’s disease research,” Rankine told Fox News Digital.
“This could make screening more efficient in averting the clinical onset of Alzheimer’s disease.”
For more Health articles, visit www.foxnews/health
“This innovation addresses a growing need and could accelerate development of new treatments, improve patient evaluation and care, and potentially even allow for early intervention before symptoms become worse,” Rankine added.
Health
Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’
NEWYou can now listen to Fox News articles!
Scientists and physicians agree that there’s been a general decline in male fertility — but they aren’t sure why.
Social media buzz has pointed to a few environmental exposures as potential factors, including cellphones and electric vehicles.
But the reality is “more complicated” than that, according to experts who recently spoke to National Geographic.
ORIGIN OF DEADLY CANCER AFFECTING YOUNG ADULTS REVEALED IN ALARMING REPORT
Although it’s not clear whether the decline is at a stage where it should be considered a crisis, numbers show that overall fertility — demographically measured by the number of babies born compared to women of child-bearing age — has decreased.
Scientists and physicians agree that there’s been a general decline in male fertility. (iStock)
Dr. Alex Robles of the Columbia University Fertility Center in New York confirmed that clinical practitioners are “certainly seeing more couples where the male factor contributes to infertility.”
CELLPHONE HEALTH RISKS IN FOCUS OF NEW GOVERNMENT STUDY: ‘VERY CONCERNED’
“At least one-third of couples we evaluate have some male component,” he told Fox News Digital.
A 2017 meta-analysis published in Oxford Journals: Human Reproduction Update found that sperm counts in Western countries have declined by almost 60% globally since 1973. The 2023 update confirmed these same results.
Urologists can track declining fertility in sperm quality, while demographic data uses the number of babies born compared to women of child-bearing age as a benchmark, according to National Geographic. (iStock)
Lead study author and epidemiologist Hagai Levine warned that this trend could lead to human extinction if it isn’t addressed.
“This is the canary in the coal mine,” Levine, public health physician at the Hebrew University-Hadassah Braun School of Public Health, told National Geographic. “It signifies that something is very wrong with our current environment, as lower sperm counts predict morbidity and mortality.”
DOCTORS WARN SOME POPULAR FOODS AND DRINKS COULD BE SECRETLY SABOTAGING MEN’S TESTOSTERONE LEVELS
These findings have been contradicted by other studies, however. A 2025 Cleveland Clinic analysis of studies from the last 53 years found sperm counts to be steady.
“There is no evidence to suggest that this decline is the cause of a precipitous decline in the ability to cause pregnancies,” primary study author Scott Lundy, a reproductive urologist at Cleveland Clinic, told National Geographic. “Most men, even with a modest decline in sperm counts, will still have no issues conceiving.”
Potential factors of decline
Multiple lifestyle factors can lead to a decline in male fertility, Robles noted, including obesity, smoking and diet, as well as environmental exposures and delayed parenthood.
National Geographic also reported that heavy drinking and marijuana use directly contribute to declining fertility and that quitting these habits, while also exercising and losing weight, can help.
Smoking of any kind can contribute to a decline in fertility, according to experts. (iStock)
Systemic inflammation, infection and disease can also have a “big, profound effect on the current status of fertility,” Lundy told National Geographic.
Those who are getting over a fever from an infection, like the flu or COVID, will have a “drastically lower” sperm count for three months, he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Male infertility can also be a marker of overall health, according to Robles. “Poor semen parameters are associated with other medical conditions and may signal underlying metabolic, hormonal or environmental issues,” he told Fox News Digital.
Experts recommend seeing a doctor to discuss fertility concerns instead of relying on the internet. (iStock)
Allan Pacey, deputy dean of the Faculty of Biology, Medicine and Health at the University of Manchester, told National Geographic that the decline could be caused by increased use of contraception, as well as men waiting longer to have children or choosing not to have them at all.
CLICK HERE FOR MORE HEALTH STORIES
Microplastics have also been raised on social media as a potential culprit, but the effects are unclear, according to experts.
There is some evidence of endocrine-disrupting chemicals — which are substances found in reusable plastics and some disposable products — altering male fertility, Lundy revealed to National Geographic.
Myths busted
Concerns have circulated on social media that keeping a cellphone in a front pocket could harm male fertility. While Lundy said such an effect is biologically possible, there is currently no scientific evidence supporting the claim.
Another common myth is that infertility is mostly a women’s issue, Robles noted, but male factors contribute to about one-third to one-half of all cases.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The claim that taking supplements can boost sperm counts is another common myth, he said, adding that it’s not backed by strong scientific evidence.
“Men should focus on factors that we know matter: maintaining a healthy weight, avoiding tobacco, limiting alcohol and managing chronic health conditions,” Robles advised.
One common myth is that infertility is mostly a women’s issue, but male factors contribute to about one-third to one-half of all cases. (iStock)
Experts recommend seeing a urologist to address fertility concerns. Robles said his approach begins with an evaluation, semen analysis, hormonal testing and medical history, while also exploring lifestyle factors.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
In addition to traditional treatment options, Robles said his fertility center also uses advanced tools that incorporate AI and robotics.
“Technologies like this are expanding options for patients who previously had very limited paths to biological parenthood,” he said.
Health
Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Lurking dementia risk exposed by breakthrough test 25 years before symptoms
Study finds link between obesity and vascular dementia
Fox News senior medical analyst Dr. Marc Siegel joins ‘America’s Newsroom’ to discuss an increase in colon cancer in people under 50 despite an overall lowering cancer deaths and a new study linking obesity to vascular dementia.
NEWYou can now listen to Fox News articles!
A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.
That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.
The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release.
KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS
The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.
After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia.
A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)
Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.
“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital.
“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”
“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.
This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.
A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)
“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.
This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.
The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release.
“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)
“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”
Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
More research is needed before this approach can be considered for clinical use prior to cognitive symptoms.
Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.
CLICK HERE FOR MORE HEALTH STORIES
“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”
-
Wisconsin1 week agoSetting sail on iceboats across a frozen lake in Wisconsin
-
Massachusetts1 week agoMassachusetts man awaits word from family in Iran after attacks
-
Detroit, MI5 days agoU.S. Postal Service could run out of money within a year
-
Pennsylvania6 days agoPa. man found guilty of raping teen girl who he took to Mexico
-
Miami, FL7 days agoCity of Miami celebrates reopening of Flagler Street as part of beautification project
-
Sports7 days agoKeith Olbermann under fire for calling Lou Holtz a ‘scumbag’ after legendary coach’s death
-
Michigan2 days agoOperation BBQ Relief helping with Southwest Michigan tornado recovery
-
Virginia1 week agoGiants will hold 2026 training camp in West Virginia